(US) Select Premarket Movers
Thu, 05 Mar 2015 9:19 AM EST
Upside:
-KYTH +25% (FDA staff notes show ATX-101 presents a consistent & favorable safety profile)
-BIOL +22% (earnings)
-EYES +20% (first successful implantation of the Argus II retinal prosthesis system)
-MVIS +14% (licensed PicoP display tech to Fortune Global 100 partner)
-CLDN +14% (initiated with Buy at Roth; expected to announce pivotal trial results from CUPID-2 trial in April '15)
-ARWR +11% (acquired NVS's RNAi R&D portfolio)
-TEAR +11% (announced $35M term loan agreement with CRG)
-PCYC +10% (being acquired by ABBV)
-VSLR +8.5% (earnings)
-MAC +7.3% (SPG said to have made takeover approach)
-MLR +7% (earnings)
-GDOT +6.3% (raised to Outperform from Neutral by Credit Suisse)
-KR +5.3% (earnings)
-RNDY +5.7% (earnings)
- CSIQ +5% (earnings, to form YieldCo)
-MBLY +4.4% (hearing strength attributed to introduction of the 4th generation system-on-chip the Eye4 engineering samples of EyeQ4 expected by Q4 FY15)
-MNK +2.4% (expands hospitals growth platform with Ikaria)
-COST +2.3% (earnings)
-HRTG +2% (earnings)
-SPG +0.8% (said to have made takeover offer for MAC)
Downside:
-ERJ -14% (earnings and FCF may be negative in FY15 due to heavy investment spending)
-VNDA -7% (announced Tradipitant Phase 2 proof of concept study results)
-JOY -6.7% (earnings)
-ABBV -6% (acquiring PCYC)
-HRB -4.3% (earnings)
-ACHN -4% (earnings)
-ARI -3.8% (offering 10M shares of common stock)
-DRII -3.2% (upsized offering to 6.7M share priced at $33.75/shr)
-HTLD -1% (priced 3.25M shares at $23.75/shr)
-GD -0.3% (increased dividend 11%)
Наверх
(US) Select Premarket Movers
Мар 05 2015, 17:35Thu, 05 Mar 2015 9:19 AM EST
Upside:
-KYTH +25% (FDA staff notes show ATX-101 presents a consistent & favorable safety profile)
-BIOL +22% (earnings)
-EYES +20% (first successful implantation of the Argus II retinal prosthesis system)
-MVIS +14% (licensed PicoP display tech to Fortune Global 100 partner)
-CLDN +14% (initiated with Buy at Roth; expected to announce pivotal trial results from CUPID-2 trial in April '15)
-ARWR +11% (acquired NVS's RNAi R&D portfolio)
-TEAR +11% (announced $35M term loan agreement with CRG)
-PCYC +10% (being acquired by ABBV)
-VSLR +8.5% (earnings)
-MAC +7.3% (SPG said to have made takeover approach)
-MLR +7% (earnings)
-GDOT +6.3% (raised to Outperform from Neutral by Credit Suisse)
-KR +5.3% (earnings)
-RNDY +5.7% (earnings)
- CSIQ +5% (earnings, to form YieldCo)
-MBLY +4.4% (hearing strength attributed to introduction of the 4th generation system-on-chip the Eye4 engineering samples of EyeQ4 expected by Q4 FY15)
-MNK +2.4% (expands hospitals growth platform with Ikaria)
-COST +2.3% (earnings)
-HRTG +2% (earnings)
-SPG +0.8% (said to have made takeover offer for MAC)
Downside:
-ERJ -14% (earnings and FCF may be negative in FY15 due to heavy investment spending)
-VNDA -7% (announced Tradipitant Phase 2 proof of concept study results)
-JOY -6.7% (earnings)
-ABBV -6% (acquiring PCYC)
-HRB -4.3% (earnings)
-ACHN -4% (earnings)
-ARI -3.8% (offering 10M shares of common stock)
-DRII -3.2% (upsized offering to 6.7M share priced at $33.75/shr)
-HTLD -1% (priced 3.25M shares at $23.75/shr)
-GD -0.3% (increased dividend 11%)